医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Notice of Personnel Changes to Corporate Officers at SanBio Co., Ltd. and at US Subsidiary SanBio, Inc.

2018年10月03日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

SanBio Co., Ltd. and US subsidiary SanBio, Inc. conducted the following personnel transfers, effective October 1, 2018.

1. Transfer Details
Akihiro Tsujimura will become a senior corporate officer for SanBio Co., Ltd. and assume the office of CEO for US subsidiary SanBio, Inc. The goal of this transfer is to support the overall development of the SanBio Group (SanBio Co, Ltd. and SanBio, Inc.). Changes accompanying Mr. Tsujimura’s appointment to these offices will be as follows:

 

SanBio Co, Ltd.

          Former title       New title  
  Akihiro Tsujimura             Senior Corporate Officer  
 
 

SanBio, Inc.

          Former title       New title  
  Toru Kawanishi     Co-CEO      
  Keita Mori     Co-CEO, Chairman     Chairman  
  Akihiro Tsujimura             CEO  
 

2. Career summary for Akihiro Tsujimura, new senior corporate officer and SanBio, Inc. CEO

Name   Career summary
1992   Joined Nichimen Corporation (now Sojitz Corporation)
2001 President & CEO of Biaxis Packaging Sales Inc., a joint venture company of Nichimen Corporation
Akihiro Tsujimura 2004 Joined Santen Pharmaceutical Co., Ltd.
(born December 26, 1967) 2012 Corporate Officer at Santen Pharmaceutical Co., Ltd.; President and CEO of Santen Inc.
2015 Senior Corporate Officer, Head of Asia Division, at Santen Pharmaceutical Co., Ltd.
2016 Executive Corporate Officer, Asia and North America Businesses, Head of Asia Division, at Santen Pharmaceutical Co., Ltd.; President and CEO of Santen Inc.
    2017   Member of the Board, Santen Pharmaceutical Co., Ltd.
 

3. Concerning Mr. Akihiro Tsujimura’s Involvement with the SanBio Group
Mr. Tsujimura possesses a wide range of experience in business administration, collected while he was working with Nichimen Corporation (now Sojitz Corporation), where he performed duties such as establishing and managing new overseas companies and advancing corporate revitalization in Japan. He also accumulated a wealth of pharmaceutical business experience at Santen Pharmaceutical Co., Ltd., a major pharmaceutical company where he concluded sales license agreements with a diverse range of other companies, conducted M&A, and managed overseas expansion. SanBio expects that Mr. Tsujimura will make use of his valuable pharmaceutical and overseas business administration experience to conduct organizational management as CEO of the Group’s US subsidiary, SanBio Inc., and become a driving force for SanBio’s future global expansion as a corporate officer.

Upon his appointment as senior corporate officer and CEO of US subsidiary SanBio, Inc., Mr. Tsujimura said, “Creating a future with Regenerative Cell Medicine…as these words show, the medical industry is undergoing enormous changes due to regenerative medicine and SanBio has been taking on challenges in the field of regenerative cell medicine for many years. I believe that SanBio will be an exciting place for me to work and also a place where I can thoroughly demonstrate the experience I have accumulated up until now. As a member of the management team, I will do my very best to help SanBio successfully expand not only throughout Japan but throughout the entire world.”

Representative Director and President Mori added, “I am overjoyed that we were able to welcome Mr. Akihiro Tsujimura as a member of the SanBio Group’s management team. As we undergo major transitions from the research and development phase to the manufacturing and sales phases, I have faith that Mr. Tsujimura can use his experience from working at large companies and his ability to start up expansive businesses to contribute to our global expansion in the future.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20181002006169/en/

CONTACT

For more information, contact:
SanBio Co., Ltd.
Masahito
Kumagae, +81-3-6264-3481
Management Administration

同じカテゴリーの記事 

  • 专业生产HemoHIM的韩国领先企业Kolmar BNH年研发投入销售占比超过2%
  • ヘモヒム製造が専門の韓国大手コルマーBNH、研究開発に年間売上高の2%を充当
  • AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
  • Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D